HE4CA125联合检测在卵巢癌诊断中价值.docVIP

HE4CA125联合检测在卵巢癌诊断中价值 　　[摘要] 目的 探讨HE4、CA125联合检测在卵巢癌诊断中的价值。 方法 选择2013年3月～2014年1月我院收治的卵巢癌患者20例为研究对象，良性病变26例为良性疾病组，另外选择同期在我院体检中心体检合格的健康妇女30例为健康对照组；比较各组的HE4、CA125水平及CA125、HE4及二者联合检测诊断卵巢癌的阳性率。 结果 卵巢癌组患者及良性疾病组的HE4、CA125水平分别显著高于健康对照组，差异有统计学意义（P0.05）；卵巢癌组患者HE4、CA125水平明显高于良性疾病组，差异有统计学意义（P0.05）；良性疾病组患者HE4、CA125水平与健康对照组比较，差异无统计学意义（P＞0.05）。CA125和HE4联合检测诊断卵巢癌的阳性率达85.0%，明显高于单独CA125、HE4 检测阳性率，差异有统计学意义（P0.05）。 结论 CA125和HE4二者联合检测可提高诊断卵巢癌的阳性率，其联合检测的诊断价值优于单项检测的价值，值得推广和应用。 　　[关键词] 卵巢癌；HE4；CA125；联合检测 　　[中图分类号] R737.31[文献标识码] B[文章编号] 1673-9701（2014）19-0071-02 　　 　　The clinical diagnostic value of HE4 combined CA125 detection of ovarian cancer 　　YANG Yuanhui CHEN Yan’e WANG Yongqiang 　　Department of Laboratory, Shenzhen Hospital of Peking University, Shenzhen 518036,China 　　[Abstract] Objective To investigate clinical diagnostic value of HE4 combined CA125 detection of ovarian cancer. Methods Selected Ovarian cancer patients from November 2013 to January 2014 in our hospital 20 cases for the study, as well as benign lesions in 26 cases, another choose the same period in our hospital medical center medical clearance in healthy women 30 cases of healthy control group , HE4, CA125 levels were compared. Results HE4, CA125 levels in patients with ovarian cancer and benign disease group were significantly higher than the healthy control group,the difference was significant（P0.05）. CA125 and HE4 combined diagnosis of ovarian cancer, the positive rate of 89.3% , significantly higher than the single CA125, HE4 test positive rates , the difference was statistically significant（P0. 05）. Conclusion CA125 and HE4 Combined detection can improve the diagnostic yield of ovarian cancer , the diagnostic value than the value of its joint detection of individual testing , worthy of promotion and application. 　　[Key words] Ovarian cancer; HE4; CA125; Joint detection 　　 　　卵巢癌是女性生殖系统最常见的三大恶性肿瘤之一，近年来发病率逐年上升，已成为严重威胁妇女健康的一种恶性疾病[1]。卵巢癌发病隐匿，早期诊断率不高，70%发现时已为中晚期，因此，早期诊断对卵巢癌的治疗及预后具有重要的临床意义[2]。CA125（糖类抗原125）